Pharmaceuticals & Therapeutics

The firm continues its monthly dividend while positioning its funds to capitalize on global instability, doubling down on defense, gold, and energy sectors.

Groundbreaking Hong Kong research uncovers why the common ‘Asian Flush’ gene dramatically worsens heart attack outcomes, paving the way for new treatments.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

Genenta's rebrand to Saentra Forge signals a major shift into Italian national security, as its CEO gains a key government-backed diplomatic post.

Colgate-Palmolive signals confidence with its 63rd annual dividend hike and appoints Bristol Myers Squibb's CEO to its board, a strategic health pivot.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

With new clinical data and a clear path to Phase 2 trials, Gain Therapeutics' GT-02287 offers hope for a disease-modifying therapy for Parkinson's.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

After a massive divestiture and balance sheet overhaul, Elutia is all-in on its next-gen biomatrix, NXT-41x, to disrupt the $1.5B breast surgery market.

The Personalized Health Association launches to modernize U.S. policy, sparking debate over innovation, patient safety, and the future of tailored care.

Belize launches a landmark partnership to combat preventable blindness, aiming to provide affordable eye care to all. But can it overcome systemic challenges?

A new clinic led by one of under 500 board-certified vet oncologists offers Seattle a personalized alternative to corporate pet healthcare.

The deal with Ahngook Pharm for its GMRx2 single-pill therapy marks a key step in a global strategy validated by recent US FDA approval.

After a tense battle with delisting threats, medical technology firm Lifeward has secured its Nasdaq status, clearing the way to refocus on its mission.

The biopharma firm's new dividend policy reflects strong 2025 results and a dual strategy of rewarding shareholders while funding M&A and expansion.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.